Schond Greenway

Schond Greenway is an accomplished financial executive with extensive experience in the life sciences and biotechnology sectors. Currently serving as Chief Financial Officer at KaliVir Immunotherapeutics, Greenway previously held CFO roles at MindMed and Avalo Therapeutics, providing strategic financial guidance and support to executive leadership. With a background in investor relations from Mesoblast Limited and Halozyme Therapeutics, Greenway has successfully managed relationships with institutional investors and analysts. Prior experience includes positions at CastleOak Securities, Barclays Capital, DURECT Corporation, Morgan Stanley, and Bank of America, contributing to expertise in corporate finance, M&A, and strategic planning. Greenway holds an MBA from the University of Virginia Darden School of Business and a B.S. in Computer/Information Technology Administration and Management from Florida Agricultural and Mechanical University.